Monte Rosa Therapeutics (GLUE) Expected to Announce Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.2396) per share and revenue of $33.87 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. The business had revenue of $8.97 million for the quarter, compared to analysts’ expectations of $12.91 million. On average, analysts expect Monte Rosa Therapeutics to post ($1.13) EPS for the current fiscal year and ($1.55) EPS for the next fiscal year.

Monte Rosa Therapeutics Stock Down 2.1%

GLUE stock opened at $10.41 on Wednesday. Monte Rosa Therapeutics has a 52-week low of $9.68 and a 52-week high of $25.77. The stock’s fifty day simple moving average is $11.94 and its 200-day simple moving average is $17.29. The stock has a market capitalization of $888.08 million, a price-to-earnings ratio of -5.91 and a beta of 1.40.

Analyst Upgrades and Downgrades

Several research firms recently commented on GLUE. JPMorgan Chase & Co. dropped their target price on Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Monday, July 27th. TD Cowen raised Monte Rosa Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Wedbush restated an “outperform” rating and issued a $27.00 price target on shares of Monte Rosa Therapeutics in a report on Wednesday, September 9th. Finally, Benchmark restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.67.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing molecular glue degraders, a class of medicines designed to eliminate disease-causing proteins by directing them to the cell’s natural protein-degradation machinery. The company’s approach is intended to address targets that may be difficult to inhibit with conventional small-molecule drugs.

Monte Rosa uses its QuEEN platform to discover and optimize molecular glue degraders for diseases involving dysregulated immune responses and other biological pathways.